Hershey Trust Company’s CRISPR Therapeutics CRSP Stock Holding History

Hershey Trust Company’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-33,758	Closed	-$1.53M	–	6
2023 Q3	$1.53M	Hold	33,758	–	–	0.01%	4
2023 Q2	$1.9M	Hold	33,758	–	–	0.01%	5
2023 Q1	$1.53M	Hold	33,758	–	–	0.01%	4
2022 Q4	$1.37M	Hold	33,758	–	–	0.01%	5
2022 Q3	$2.21M	Hold	33,758	–	–	0.02%	5
2022 Q2	$2.05M	Hold	33,758	–	–	0.02%	13
2022 Q1	$2.12M	Hold	33,758	–	–	0.02%	15
2021 Q4	$2.56M	Hold	33,758	–	–	0.02%	15
2021 Q3	$3.78M	Buy	33,758 +9,234	+38%	+$1.16M	0.04%	11
2021 Q2	$3.97M	Buy	24,524 +7,645	+45%	+$930K	0.04%	8
2021 Q1	$2.06M	Buy	+16,879	New	+$2.55M	0.02%	8
2020 Q4	–	Sell	-4,925	Closed	-$412K	–	33
2020 Q3	$412K	Buy	+4,925	New	+$437K	﹤0.01%	12
2017 Q4	–	Sell	-42,991	Closed	-$768K	–	18
2017 Q3	$768K	Buy	+42,991	New	+$780K	0.01%	9

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Hershey Trust Company's CRSP Position: Q4 2023 in Review

Hershey Trust Company sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 33,758 shares — an estimated $1.53M sold.

Hershey Trust Company first reported a position in CRSP in Q3 2017 and held it in 13 quarters. The position peaked at $3.97M in Q2 2021. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Hershey Trust Company reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Hershey Trust Company sold 33,758 CRISPR Therapeutics shares in Q4 2023, an estimated $1.53M.
Hershey Trust Company first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 13 quarters.
Hershey Trust Company's CRISPR Therapeutics position peaked at $3.97M in Q2 2021.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Hershey Trust Company's 13F filing for Q4 2023, filed 14 Feb 2024.